首页> 美国卫生研究院文献>Clinical and Molecular Allergy : CMA >SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma
【2h】

SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma

机译:意大利的SANI-严重哮喘网络:监测严重哮喘的一种方法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Even if severe asthma (SA) accounts for 5–10% of all cases of the disease, it is currently a crucial unmet need, owing its difficult clinical management and its high social costs. For this reason several networks, focused on SA have been organized in some countries, in order to select these patients, to recognize their clinical features, to evaluate their adherence, to classify their biological/clinical phenotypes, to identify their eligibility to the new biologic therapies and to quantify the costs of the disease. Aim of the present paper is to describe the ongoing Italian Severe Asthma Network (SANI). Up today 49 centres have been selected, widespread on the national territory. Sharing the same diagnostic protocol, data regarding patients with SA will be collected and processed in a web platform. After their recruitment, SA patients will be followed in the long term in order to investigate the natural history of the disease. Besides clinical data, the cost/benefit evaluation of the new biologics will be verified as well as the search of peculiar biomarker(s) of the disease.
机译:即使严重的哮喘(SA)占所有疾病病例的5-10%,由于其临床管理困难和社会成本高昂,目前仍是一项关键的未满足需求。因此,在某些国家/地区已建立了多个针对SA的网络,以选择这些患者,以识别其临床特征,评估其依从性,对他们的生物学/临床表型进行分类,以确定他们是否符合新的生物学要求。治疗和量化疾病的成本。本文的目的是描述正在进行的意大利严重哮喘网络(SANI)。迄今为止,已经选择了49个中心,分布在全国范围内。共享相同的诊断协议,有关SA患者的数据将在网络平台上收集和处理。招募后,将对SA患者进行长期随访,以调查其自然病史。除临床数据外,还将验证新生物制剂的成本/效益评估,以及寻找该疾病的独特生物标志物。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号